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multiple logit regression. The most important factors
were found to be depression or other mental health
comorbidity and previous hospitalization. Compliance
measures were not found to be important predictors.
CONCLUSIONS: It is feasible to compute compliance
measures based on Medicaid prescription claims records,
but other factors were found to be more important risk
factors for an event.
HEALTH UTILITY STUDIES I
UT1
36 INTO 1 DOESN’T GO
Kind P
University of York,York, England
OBJECTIVE: The SF-36 is a widely used generic measure
of health status. Whilst SF-36 provides a rich source 
of descriptive data, it shares a major disadvantage with
similar proﬁle measures that do not support the compu-
tation of an aggregate summary index. Proﬁle measures
of this type may demonstrate changes in overall health
status, but are inherently incapable of measuring the mag-
nitude of such change. This defect has been recognised
for some time and several remedial methods have been
proposed. These include separate algorithms published by
Fryback, Shmueli and Brazier. This paper reviews these
algorithms and considers the implications of their use 
in economic evaluation. METHODS: Journal articles
describing these three transformation models were used
as the basis of a forensic examination of the empirical evi-
dence offered in their support. The Brazier methodology,
based on a more fundamental remodeling of the SF-36,
was subjected to an extensive review that took account
of the derivation of an abbreviated descriptive system
referred to as the SF-6D. The implications of applying any
of these algorithms to the estimation of QALY gains was
tested using published results from a study that ﬁelded
the SF-36 alongside an asthma-speciﬁc measure.
RESULTS: Signiﬁcant defects in all three transforma-
tion models were identiﬁed; these included the failure of
regression models used to estimate index values and 
the imposition of researcher value judgment. The docu-
mented failure of the SF-6D models was conspicuous in
its original published account. Cost/QALY estimates
varied according to transformation model with the SF-6D
ratios being systematically lower than the others. CON-
CLUSIONS: There is demonstrable evidence that the 
SF-36 continues to be resistant to conversion into a 
single, summary index incorporating social preference
values. Continued misapplication of such transformation
methods is liable to degrade the status of cost-utility
analysis based on more robust methods of measuring
health outcomes.
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OBJECTIVES: Generic health status indexes convention-
ally require that full health and dead are valued as 1 and
0 respectively. When social preference weights for health
states are obtained using a visual analogue scaling (VAS)
technique their raw scores often lie on a scale with dif-
ferent endpoints (such as “best” and “worst” health). The
transformation of such “raw” scores to a 0–1 scale leads
to the exclusion of respondents who fail, for whatever
reason, to record a value for dead or full health. This
study reports on an alternative approach that does not
impose such strict inclusion criteria. METHODS: Data
from a postal valuation survey (n = 686) conducted in
Belgium are used to compare 2 different approaches: (a)
values for EQ-5D health states are transformed on a
within-respondent basis and median values then com-
puted; (b) median values for EQ-5D health states are
computed from the observed data and then transformed
to a 0–1 scale. Rankings, health state values and value
differences between pairs of states resulting from both
methods are compared. RESULTS: The exclusion rate
approaches 29% in the conventional approach and 5%
in the alternative approach. Transformed median valua-
tions are not signiﬁcantly different from median trans-
formed valuations. Correlation is 0.994 (p < 0.0005).
Health state rankings are identical in both approaches.
Although the value differences between pairs of states
differ between both methods, their correlation is very
high (0.998). CONCLUSIONS: Using median original
valuations in the analysis of EQ-5D valuation data are
theoretically appealing. It builds on the “median voter”
model and has the advantage of a lower respondent exclu-
sion rate. Given the need for transparency and the 
inclusive nature of the mode of analysis, aggregation of
observed VAS scores with subsequent transformation is
considered an acceptable alternative to the conventional
method with its associated data loss.
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OBJECTIVES: Policymakers need cost utility estimates
when evaluating new biologic therapies in RA. Most clin-
ical trials of these therapies measure physical function,
then estimate utility from physical function. Adalimumab
(D2E7, Abbott) trials measured both physical function
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and utility, providing an opportunity to evaluate esti-
mates of utility from physical function. METHODS: A
total of 2070 patients with active RA participated in 4
clinical trials (ARMADA, DE011, DE019 and STAR).
The Health Assessment Questionnaire Disability Index
(HAQ) measured physical function for all patients and
the Health Utilities Index Mark-3 (HUI3) measured
utility for 2000 patients at baseline and months 3 and 6.
HAQ scores range from 0 (good physical function) to 3.
HUI3 was regressed on HAQ using both repeated
measure mixed models and cross-sectional models 
controlling for age, sex, disease duration, clinical trial 
and fatigue (measured by the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F)). The cross-
sectional models used end-of-study data with Last Obser-
vation Carried Forward (LOCF) imputation. These
analyses include the 1990 patients with non-missing
values for these variables. RESULTS: The mixed models
and the cross-sectional models provided almost identical
coefﬁcient estimates. Disease duration and trial were 
not signiﬁcant and were deleted from the model. Age 
(in years) was statistically signiﬁcant but trivial (b =
0.00087). The basic estimated cross-sectional model was:
HUI3 = 0.76–0.28*HAQ + 0.05*FEMALE (p < 0.0001
for each regressor, Adj. R2 = 0.49). However, the rela-
tionship between HUI3 and HAQ appears to be nonlin-
ear: coefﬁcients for HAQ-squared and HAQ-cubed were
signiﬁcant (p = 0.013 and p = 0.003, respectively) when
added to the regression. Adding FACIT-F to the basic
cross-sectional model substantially improved model ﬁt
(Adj. R2 = 0.63). CONCLUSIONS: The basic algorithm
developed in this study is consistent with published pre-
dictions of utility from HAQ (Kobelt et al., Arthritis and
Rheumatism, 1999). However, these algorithms’ predic-
tions are limited and should only be used when direct
utility scores are not available.
SESSION III
INFECTIOUS DISEASE STUDIES II
IN4
DISCOUNTING HEALTH BENEFITS:A NOVEL
APPROACH TO ENSURE PROPER VALUING OF
VACCINATION STRATEGIES
Bos JM1, van Alphen L2, Postma MJ1
1Groningen University Institute for Drug Exploration
(GUIDE), Groningen, Netherlands; 2National Institute of Public
Health and the Environment, Bilthoven, Netherlands
OBJECTIVES: During the last ten years the inﬂuence 
of pharmacoeconomics has increased in decision-making.
Due to budget constraints, decision makers often have to
choose which intervention is given priority, for example,
using league tables. The current practice of discounting
both health and monetary beneﬁts at the same rate places
a higher priority on direct medical interventions, with
health beneﬁts occurring immediately. Due to this, pre-
ventive interventions such as vaccination strategies are
possibly under-appreciated, leading to inconsistencies.
Some researchers have suggested to not discount health
beneﬁts at all. We developed a novel approach combin-
ing the rationales underlying both theories of fully and
not-at-all discounting of health beneﬁts. We illustrate 
our novel approach with the conjugate meningococcal
B/C vaccine for newborns in the Netherlands.
METHODS: Firstly, we discard the relevance of the
Keeler-Cretin paradox for day-to-day practice. Secondly,
we note that by discounting the analyst implicitly corrects
for a number of uncertainties and preferences, which are
among others time preference and force of innovation.
Our novel approach appreciates these factors, but also
elaborates on the uncertainty that is already implicitly
covered in the concept of life-years gained, which is part
of the QALY assessment. RESULTS: Our illustration 
for vaccination with the conjugate meningococcal B/C
vaccine renders estimates per QALY gained of €16,000
(monetary ﬁgures and QALYs discounted at 4%), €7000
(monetary ﬁgures discounted at 4%, QALYs non-
discounted) and approximately €10,000 (monetary
ﬁgures at 4% and QALYs according to the novel
approach). CONCLUSIONS: We have developed a novel
approach for discounting health beneﬁts that may be 
considered a consensus approach between fully and 
not-at-all discounting of health beneﬁts. The method 
can be applied to vaccines. Its application may ensure a
more proper pharmacoeconomic valuing of vaccination 
strategies.
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OBJECTIVES: In the Netherlands, the incidence of
meningococcal C infections has strongly increased during
the last years. Should the Netherlands follow the UK 
and start a large-scale meningococcal C vaccination cam-
paign? We calculated the health effects and costs of such
a vaccination program. METHODS: The health effects,
the costs and savings, as well as the cost-effectiveness of
vaccinating all persons aged 14 months to 19 years in the
Netherlands against meningococcal C infection was esti-
mated, from a societal perspective using a decision ana-
lytic model. Data were derived from the Netherlands
Reference Laboratory for Bacterial Meningitis, the Dutch
costing guidelines, PRISMANT Healthcare, and national
and international literature. Direct and indirect costs
